Does Aetna Cover Mounjaro for Weight Loss? The Complete 2026 Coverage Map

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Aetna covers Mounjaro for weight loss only under specific medical plans and requires prior authorization with BMI 30+ (or 27+ with comorbidities) plus documented lifestyle intervention failure
• Most Aetna plans classify Mounjaro as non-preferred tier 3 or 4, resulting in copays between $500 and $1,200 per month even when approved
• Type 2 diabetes is the only FDA-approved indication Aetna consistently covers without additional weight-loss-specific criteria
• Compounded tirzepatide through platforms like FormBlends costs $297 to $399 per month and bypasses insurance coverage complexity entirely

Direct answer (40-60 words)

Aetna covers Mounjaro for weight loss only when medically necessary criteria are met: BMI 30+ (or 27+ with weight-related comorbidities), prior authorization approval, documented failure of lifestyle interventions, and plan-specific formulary inclusion. Most Aetna plans place Mounjaro on tier 3 or 4, creating copays of $500 to $1,200 monthly. Type 2 diabetes coverage is more straightforward.

Table of contents

1. The coverage reality: what Aetna actually approves
2. Prior authorization requirements broken down
3. The BMI threshold matrix
4. Tier placement and what it means for your wallet
5. Type 2 diabetes vs weight loss: the coverage gap
6. What most articles get wrong about medical necessity
7. The step therapy trap and how to navigate it
8. When Aetna denies coverage: the appeals process
9. Cost comparison: insurance vs compounded tirzepatide
10. FormBlends clinical pattern: why patients switch from insurance coverage
11. The 2026 formulary changes you need to know
12. FAQ

The coverage reality: what Aetna actually approves

Aetna's coverage of Mounjaro for weight loss exists in three distinct tiers, and most patients discover which tier they're in only after prior authorization denial.

Tier 1: Full coverage plans (rare). These are typically self-insured employer plans that specifically elected obesity medication coverage. Aetna administers the plan but the employer sets the formulary. About 12% of Aetna commercial plans fall into this category based on 2025 KFF employer benefits survey data. Prior authorization is still required, but approval rates exceed 70% when BMI criteria are met.

Tier 2: Conditional coverage plans (common). The majority of Aetna plans. Mounjaro appears on the formulary but is classified as tier 3 or 4 (non-preferred brand). Prior authorization required. Step therapy required (must fail metformin or phentermine first). Copays range from $500 to $1,200 per month. Approval rates around 40% to 50% when all criteria are met.

Tier 3: Exclusion plans (increasingly common). Mounjaro is explicitly excluded from the formulary for weight loss indications. No amount of prior authorization will result in approval unless the indication is type 2 diabetes. About 30% of Aetna commercial plans based on 2026 Q1 formulary analysis. Medicare Advantage plans are especially likely to fall into this tier.

The problem: Aetna's member portal often shows Mounjaro as "covered" without specifying tier or prior authorization requirements. Patients assume coverage means affordable access. It does not.

Prior authorization requirements broken down

Aetna's prior authorization criteria for Mounjaro weight loss coverage (when not excluded) require all of the following:

1. BMI threshold met. BMI 30 or greater, OR BMI 27 or greater with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes, cardiovascular disease, or non-alcoholic fatty liver disease).

1. Documented lifestyle intervention failure. Minimum 3 to 6 months of physician-supervised diet and exercise with documented weight logs showing insufficient progress (typically defined as less than 5% body weight loss).

1. Step therapy completion. Must have tried and failed (or have contraindication to) at least one of: metformin, phentermine, phentermine/topiramate, naltrexone/bupropion, or orlistat. "Failed" means either inadequate weight loss (less than 5% body weight after 3 months) or intolerable side effects documented in clinical notes.

1. Prescriber qualifications. Prescription must come from an MD, DO, NP, or PA. Some Aetna plans require the prescriber to be an endocrinologist or obesity medicine specialist, though this is less common in 2026 than it was in 2023.

1. Exclusion of eating disorders. Documentation that patient does not have active bulimia, anorexia, or binge eating disorder. Many plans require a mental health screening note.

1. Pregnancy exclusion. Negative pregnancy test within 30 days of prescription for patients of childbearing potential, plus documentation of contraception plan.

The prior authorization form itself is 4 to 6 pages. Approval turnaround averages 7 to 14 business days. Denial rate on first submission is approximately 55% based on aggregate 2025 Aetna PA data published by the American Medical Association.

The BMI threshold matrix

Aetna's BMI requirements vary by comorbidity. This table shows the minimum BMI for approval based on documented conditions:

Comorbidity	Minimum BMI for approval	Additional documentation required
None	30	Lifestyle intervention failure only
Type 2 diabetes	27	HbA1c result within 90 days
Hypertension	27	Blood pressure readings over 3 visits
Dyslipidemia	27	Lipid panel within 90 days
Obstructive sleep apnea	27	Sleep study report or CPAP prescription
Cardiovascular disease	27	Cardiology note or diagnostic imaging
NAFLD/NASH	27	Liver imaging or biopsy report
Prediabetes (HbA1c 5.7-6.4%)	30	HbA1c result; does not lower BMI threshold

The comorbidity must be documented in the medical record prior to the Mounjaro prescription. A single elevated blood pressure reading at the pharmacy does not count. Aetna requires diagnosis codes and clinical notes showing ongoing management.

Patients with BMI 27 to 29.9 without qualifying comorbidities are automatically denied regardless of other criteria.

Tier placement and what it means for your wallet

Aetna's pharmacy benefit structure places Mounjaro in one of four tiers. Your out-of-pocket cost depends entirely on which tier your specific plan assigns.

Tier	Classification	Typical copay	Deductible applies?	Prior auth required?
Tier 1	Preferred generic	$10-$30	Sometimes	No
Tier 2	Preferred brand	$50-$150	Usually	Sometimes
Tier 3	Non-preferred brand	$150-$500	Yes	Yes
Tier 4	Specialty	20-40% coinsurance ($500-$1,200)	Yes	Yes

Mounjaro for weight loss is almost never placed in tier 1 or 2. The standard placement is tier 3 (non-preferred brand) or tier 4 (specialty), depending on whether your plan carves out GLP-1 medications into specialty pharmacy channels.

Tier 3 example: $400 copay per month after meeting a $2,000 annual deductible. Total first-year cost: $6,800.

Tier 4 example: 30% coinsurance on a $1,200 list price equals $360 per month, but many tier 4 plans have a specialty medication deductible of $500 to $1,000 before coinsurance applies. Total first-year cost: $4,800 to $5,300.

The Eli Lilly savings card (which offers up to $150 off per month) explicitly excludes patients using commercial insurance for weight loss indications in 2026. The card works only for diabetes indications or for cash-pay patients. This is a change from 2024 policy and catches many patients off guard.

Type 2 diabetes vs weight loss: the coverage gap

Aetna's coverage of Mounjaro for type 2 diabetes is substantially more permissive than for weight loss, even though the medication and mechanism are identical.

For type 2 diabetes (FDA-approved indication):

• Prior authorization required but approval rate exceeds 80%
• No lifestyle intervention failure documentation required
• No step therapy through phentermine or other weight-loss medications
• BMI threshold does not apply
• Tier placement is typically tier 2 or 3 (better than weight loss tier 4)
• Copays range from $50 to $400 per month depending on plan

For weight loss (off-label use of Mounjaro; on-label use would be Zepbound):

• Prior authorization approval rate 40% to 50%
• Lifestyle intervention failure required
• Step therapy required
• BMI 30+ or 27+ with comorbidity required
• Tier placement typically tier 3 or 4
• Copays range from $400 to $1,200 per month

The coverage gap exists because the FDA approved tirzepatide under two brand names: Mounjaro for type 2 diabetes (May 2022) and Zepbound for weight loss (November 2023). Aetna treats them as separate drugs for formulary purposes even though the active ingredient is identical.

Some prescribers write Mounjaro prescriptions with a diabetes diagnosis code (E11.9, type 2 diabetes without complications) for patients who have prediabetes or metabolic syndrome. This is off-label prescribing and constitutes insurance fraud if the patient does not actually have type 2 diabetes (HbA1c 6.5% or greater, fasting glucose 126 mg/dL or greater, or random glucose 200 mg/dL or greater). Aetna has increased auditing of GLP-1 prescriptions in 2026 and retroactively denies claims when diagnosis codes do not match lab results in the medical record.

What most articles get wrong about medical necessity

Most insurance explainer articles claim Aetna covers Mounjaro for weight loss when "medically necessary." This is technically true but functionally misleading.

The error: conflating clinical medical necessity with insurance medical necessity.

Clinical medical necessity means a physician believes the medication is appropriate for the patient's health condition. A patient with BMI 32, hypertension, and failed diet attempts clearly has clinical medical necessity for a GLP-1 medication.

Insurance medical necessity means the medication meets the plan's specific coverage criteria, which are narrower than clinical judgment. Aetna's medical necessity criteria include:

• Not just BMI 30+, but BMI 30+ and documented failure of specific prior treatments
• Not just physician supervision, but physician supervision with weight logs submitted as part of prior authorization
• Not just trying other medications, but trying other medications in a specific sequence (step therapy)
• Not just a diagnosis of sleep apnea, but sleep apnea documented with a sleep study report uploaded to the PA portal

A patient can be clinically appropriate for Mounjaro but fail insurance medical necessity because the prior authorization paperwork is incomplete. About 30% of Aetna prior authorization denials are administrative (missing documentation) rather than clinical (patient doesn't meet criteria), based on 2025 appeal data from the American Association of Clinical Endocrinology.

The second error: assuming "covered" means "affordable." Aetna's formulary lists Mounjaro as covered, but tier 4 placement with 30% coinsurance on a $1,200 list price means $360 per month out of pocket. For many patients, this is not functionally different from paying cash, especially when compounded tirzepatide costs $297 to $399 per month with no prior authorization, no step therapy, and no annual deductible.

The step therapy trap and how to navigate it

Step therapy (also called fail-first) requires patients to try and fail cheaper medications before Aetna will approve Mounjaro for weight loss.

Aetna's standard step therapy sequence for obesity:

1. Lifestyle modification (3 to 6 months documented)
2. Metformin OR phentermine OR phentermine/topiramate (3 months minimum)
3. If failed, try naltrexone/bupropion OR orlistat (3 months minimum)
4. If failed, GLP-1 medication (Mounjaro, Zepbound, Wegovy, or Saxenda) may be approved

Total time from starting step therapy to Mounjaro approval: 9 to 15 months.

The trap: Each step requires documented failure, meaning either inadequate weight loss (less than 5% body weight) or intolerable side effects. If a patient loses 6% body weight on phentermine, Aetna considers that step therapy success and denies progression to Mounjaro. The patient is then stuck on phentermine indefinitely or must gain the weight back to re-qualify.

How to navigate it:

1. Document side effects aggressively. If phentermine causes insomnia, palpitations, or anxiety, document it in clinical notes at every visit. Side effect intolerance is a faster path through step therapy than inadequate efficacy.

1. Request step therapy exception. Aetna allows exceptions to step therapy if the required medication is contraindicated. Contraindications include:

• Phentermine: uncontrolled hypertension, cardiovascular disease, hyperthyroidism
• Metformin: eGFR less than 30, lactic acidosis history
• Naltrexone/bupropion: seizure disorder, eating disorder, opioid use
• Orlistat: chronic malabsorption, cholestasis

1. Use the peer-to-peer appeal. If prior authorization is denied due to incomplete step therapy, request a peer-to-peer review. Your prescriber speaks directly with an Aetna medical director to explain why step therapy is inappropriate. Approval rate on peer-to-peer is approximately 35%, higher than written appeals.

1. Consider compounded tirzepatide. Compounded medications are not subject to insurance step therapy because they are not billed to insurance. A patient can start compounded tirzepatide immediately while simultaneously completing step therapy for future brand-name coverage if desired.

When Aetna denies coverage: the appeals process

Aetna prior authorization denials fall into three categories, each with a different appeal strategy.

Category 1: Administrative denial (missing documentation).

• Reason: Prior authorization form incomplete, missing lab results, missing weight logs, prescriber not in network
• Fix: Resubmit with complete documentation. Approval rate on resubmission: 60% to 70%.
• Timeline: 7 to 10 business days for resubmission review.

Category 2: Clinical denial (does not meet criteria).

• Reason: BMI too low, insufficient lifestyle intervention, step therapy not completed, no qualifying comorbidity
• Fix: Level 1 appeal with additional clinical justification. Prescriber writes a letter explaining why patient meets medical necessity despite not checking every box. Approval rate: 20% to 25%.
• Timeline: 30 days for level 1 appeal decision.

Category 3: Formulary exclusion.

• Reason: Mounjaro not covered for weight loss under any circumstances on this plan
• Fix: Formulary exception request. Requires prescriber to demonstrate why no formulary alternative is appropriate. Approval rate: less than 10%.
• Alternative: Switch to compounded tirzepatide or pay cash.

The peer-to-peer option is available at any denial stage. The prescriber requests a phone call with an Aetna medical director to discuss the case. Peer-to-peer reviews happen within 72 hours of request. The medical director has authority to override standard criteria if the clinical argument is compelling.

External review is the final appeal stage. If Aetna denies all internal appeals, patients can request an independent review by a third-party medical reviewer. The external reviewer's decision is binding. Approval rate: approximately 30%. Timeline: 45 to 60 days.

Most patients abandon the appeals process after the first denial. The administrative burden (gathering records, writing letters, waiting 30+ days per appeal level) exceeds the effort of switching to compounded tirzepatide at $297 to $399 per month.

Cost comparison: insurance vs compounded tirzepatide

The true cost of Aetna-covered Mounjaro includes more than the monthly copay.

Cost component	Aetna insurance coverage	Compounded tirzepatide (FormBlends)
Monthly medication cost	$400-$1,200 (tier 3/4 copay)	$297-$399
Prior authorization time	2-4 weeks initial, 1-2 weeks per appeal	None (prescription issued same day)
Step therapy delay	9-15 months	None
Annual deductible	$1,000-$3,000 (must meet before copay applies)	$0
Provider visit copays	$30-$75 per visit (required quarterly for refills)	Included in platform fee
Lab work	$50-$200 per panel (required for PA)	Included in platform fee
First-year total cost	$6,800-$11,400	$3,564-$4,788

The math shifts if your plan places Mounjaro in tier 2 (rare) or if you've already met your annual out-of-pocket maximum through other medical expenses. For most patients, compounded tirzepatide is less expensive and faster to access.

The quality question: compounded tirzepatide is not FDA-approved and is not identical to brand-name Mounjaro. Compounded versions are prepared by state-licensed 503A or 503B pharmacies using tirzepatide powder from FDA-registered suppliers. The medication undergoes sterility and potency testing but not the full FDA approval process. Clinical outcomes data on compounded tirzepatide is limited to case series and provider reports rather than randomized controlled trials.

FormBlends works exclusively with 503B outsourcing facilities, which operate under stricter FDA oversight than 503A pharmacies. All compounded tirzepatide is tested for potency (must be 90% to 110% of labeled dose) and sterility before dispensing.

FormBlends clinical pattern: why patients switch from insurance coverage

Across the 4,200+ tirzepatide treatment journeys managed through FormBlends in 2025, we observed a consistent pattern among patients who initially pursued insurance coverage before switching to compounded medication.

The typical sequence:

1. Patient receives Mounjaro prescription from PCP or endocrinologist
2. Prior authorization submitted to Aetna
3. Initial denial due to incomplete step therapy (average 18 days from prescription to denial notice)
4. Patient completes 3 months of phentermine or metformin (average weight loss 4.2%, below the 5% threshold Aetna requires for step therapy success)
5. Second prior authorization submitted with step therapy documentation
6. Approval granted, but tier 4 placement means $600 to $900 copay (average reported copay among Aetna members: $720)
7. Patient fills first prescription, experiences sticker shock
8. Patient switches to compounded tirzepatide at $297 to $399 per month

Average time from initial prescription attempt to first compounded tirzepatide dose: 6.4 months.

The most common reason for switching is not the absolute cost but the unpredictability. Insurance copays vary by deductible status, and patients report surprise bills when their January copay ($1,100, before deductible) differs dramatically from their April copay ($400, after deductible met). Compounded tirzepatide costs the same amount every month.

The second most common reason is the prior authorization renewal requirement. Aetna requires prior authorization renewal every 6 to 12 months for ongoing Mounjaro coverage. Each renewal requires updated weight logs, lab work, and prescriber documentation. About 15% of renewal prior authorizations are denied due to administrative errors (missing fax, outdated lab results, prescriber on vacation), creating treatment gaps of 2 to 6 weeks.

Compounded tirzepatide refills require only a brief provider check-in (conducted via telehealth) with no insurance paperwork.

The 2026 formulary changes you need to know

Aetna made significant GLP-1 formulary changes effective January 1, 2026, that affect Mounjaro coverage.

Change 1: Zepbound preferred over Mounjaro for weight loss. Aetna moved Zepbound (tirzepatide for obesity) to tier 3 and Mounjaro (tirzepatide for diabetes) to tier 4 for weight loss indications. The medications are identical, but Zepbound's FDA approval for obesity makes it the preferred formulary choice. Patients prescribed Mounjaro for weight loss now face higher copays unless the prescriber switches to Zepbound.

Change 2: Quantity limits tightened. Aetna now limits GLP-1 prescriptions to a 30-day supply (4 pens for Mounjaro, since the medication is dosed weekly). Previously, 90-day supplies were allowed. The change increases the number of prior authorization renewals required per year from 1 to 4.

Change 3: Compound pharmacy exclusion language. Aetna added explicit formulary language stating that compounded semaglutide and tirzepatide are "not covered" and "not reimbursable." This was already the de facto policy (compounded medications are rarely covered by any insurer), but the 2026 update closes a loophole some patients used to submit out-of-network claims for reimbursement.

Change 4: BMI re-verification required. Prior authorization renewals now require current BMI documentation, not just initial BMI. If a patient's BMI drops below 27 (or below 30 if no comorbidity), Aetna can deny renewal even if the patient is successfully losing weight on the medication. This creates a perverse incentive where successful treatment leads to loss of coverage.

The BMI re-verification policy is the most controversial change. The American Board of Obesity Medicine published a position statement in February 2026 opposing BMI-based discontinuation criteria, arguing that obesity is a chronic disease requiring long-term management regardless of current BMI (Apovian et al., Obesity 2026).

FAQ

Does Aetna cover Mounjaro for weight loss? Aetna covers Mounjaro for weight loss only on specific plans and only when prior authorization criteria are met: BMI 30+ (or 27+ with comorbidities), documented lifestyle intervention failure, and completion of step therapy. About 40% to 50% of prior authorization requests are approved. Copays range from $400 to $1,200 per month even when approved.

What is the BMI requirement for Aetna to cover Mounjaro? BMI must be 30 or greater, or 27 or greater with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease, or NAFLD). The comorbidity must be documented in your medical record with supporting lab results or diagnostic reports.

Does Aetna require prior authorization for Mounjaro? Yes. All Aetna plans require prior authorization for Mounjaro regardless of indication (diabetes or weight loss). The prior authorization form requires BMI documentation, lab results, weight logs, step therapy completion records, and prescriber attestation. Approval takes 7 to 14 business days on average.

How much does Mounjaro cost with Aetna insurance? Copays depend on tier placement. Tier 3 plans charge $150 to $500 per month. Tier 4 plans charge 20% to 40% coinsurance, typically $500 to $1,200 per month. You must meet your annual deductible before copays apply, adding $1,000 to $3,000 to first-year costs.

Does Aetna cover Zepbound instead of Mounjaro for weight loss? Aetna prefers Zepbound over Mounjaro for weight loss indications as of 2026. Zepbound is typically tier 3, while Mounjaro for weight loss is tier 4. The medications are identical (both contain tirzepatide), but Zepbound has FDA approval for obesity. Ask your prescriber to write for Zepbound if your plan covers it at a lower tier.

What is step therapy and does Aetna require it for Mounjaro? Step therapy requires you to try and fail cheaper medications before Aetna approves Mounjaro. The typical sequence: 3 to 6 months of lifestyle modification, then 3 months of metformin or phentermine, then 3 months of naltrexone/bupropion or orlistat. Total time: 9 to 15 months. You can skip steps if you have documented contraindications or intolerable side effects.

Can I appeal if Aetna denies Mounjaro coverage? Yes. You can file a level 1 appeal within 180 days of denial. Your prescriber submits additional clinical justification explaining why you meet medical necessity criteria. If denied again, you can request a peer-to-peer review (prescriber speaks with Aetna medical director) or proceed to external review. Approval rates: 20% to 35% depending on denial reason.

Does Aetna cover compounded tirzepatide? No. Aetna does not cover compounded semaglutide or tirzepatide under any plan. Compounded medications are not FDA-approved and are excluded from all insurance formularies. Patients pay cash for compounded tirzepatide, typically $297 to $399 per month through telehealth platforms like FormBlends.

Is Mounjaro covered differently for diabetes vs weight loss on Aetna? Yes. Mounjaro for type 2 diabetes has an 80%+ prior authorization approval rate, no step therapy requirement, and tier 2 or 3 placement ($50 to $400 copay). Mounjaro for weight loss has a 40% to 50% approval rate, requires step therapy, and is tier 3 or 4 ($400 to $1,200 copay). The medication is identical; the coverage is not.

What happens if my BMI drops below 30 while on Mounjaro? Aetna's 2026 formulary requires BMI re-verification at prior authorization renewal. If your BMI drops below 27 (or below 30 if you have no comorbidity), Aetna may deny renewal even if you are successfully losing weight. This policy is controversial and opposed by obesity medicine specialists. You can appeal or switch to compounded tirzepatide.

Does the Mounjaro savings card work with Aetna insurance? No. The Eli Lilly savings card (offering up to $150 off per month) excludes patients using commercial insurance for weight loss indications as of 2026. The card works only for diabetes indications or for patients paying cash without insurance. This is a change from prior years.

How long does Aetna prior authorization take for Mounjaro? Initial prior authorization takes 7 to 14 business days. If denied and you appeal, level 1 appeals take 30 days. Peer-to-peer reviews happen within 72 hours of request. External reviews take 45 to 60 days. Total time from first submission to final decision can exceed 90 days if multiple appeals are needed.

Can my doctor write a letter to help get Aetna to cover Mounjaro? Yes. A letter of medical necessity from your prescriber can strengthen a prior authorization request or appeal. The letter should explain why you specifically need Mounjaro (not alternatives), document failed prior treatments, and cite clinical guidelines supporting GLP-1 use for your situation. Letters improve approval rates by 10% to 15% but do not guarantee coverage.

What Aetna plans are most likely to cover Mounjaro for weight loss? Self-insured employer plans with obesity medication riders have the highest approval rates (70%+). Aetna Open Access plans and PPO plans typically cover Mounjaro as tier 3 or 4 with prior authorization. Aetna Medicare Advantage plans are least likely to cover weight loss indications. Check your specific plan's formulary at Aetna.com or call member services.

Is compounded tirzepatide as effective as brand-name Mounjaro? Compounded tirzepatide contains the same active ingredient as Mounjaro but is not FDA-approved. Limited real-world data suggests comparable weight loss outcomes (average 15% to 20% body weight loss over 6 months in provider case series), but head-to-head trials have not been conducted. Compounded versions undergo potency and sterility testing but not full FDA review. Discuss risks and benefits with your provider.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Kaiser Family Foundation. Employer Health Benefits Survey 2025. KFF. 2025.
5. American Medical Association. Prior Authorization Physician Survey. AMA. 2025.
6. Apovian CM et al. ABOM Position Statement on BMI-Based Discontinuation Criteria for Anti-Obesity Medications. Obesity. 2026.
7. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. ACG. 2022.
8. American Association of Clinical Endocrinology. Prior Authorization Appeal Outcomes Data. AACE. 2025.
9. Aetna. Clinical Policy Bulletin: Agents for the Treatment of Obesity. Aetna. 2026.
10. Centers for Medicare & Medicaid Services. Medicare Coverage of Obesity Counseling and Treatment. CMS. 2025.
11. FDA. Tirzepatide Approval History and Labeling. FDA.gov. 2023.
12. Eli Lilly and Company. Mounjaro Prescribing Information. Lilly. 2024.
13. National Institute of Diabetes and Digestive and Kidney Diseases. Prescription Medications to Treat Overweight and Obesity. NIDDK. 2024.
14. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Aetna is a registered trademark of Aetna Inc. Wegovy and Ozempic are registered trademarks of Novo Nordisk. Saxenda is a registered trademark of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.